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Abstract Hepatocellular carcinoma (HCC) is a primary
malignant tumor of the liver that accounts for an important
health problem worldwide. Only 10–15% of HCC patients
are suitable candidates for hepatic resection and liver
transplantation due to the advanced stage of the disease at
time of diagnosis and shortage of donors. Therefore, several
minimally invasive image-guided therapies for locoregional
treatment have been developed. Tumor ablative techniques
are either based on thermal tumor destruction, as in
radiofrequency ablation, cryoablation, microwave ablation,
laser ablation and high-intensity focused ultrasound, or
chemical tumor destruction, as in percutaneous ethanol
injection. Image-guided catheter-based techniques rely on
intra-arterial delivery of embolic, chemoembolic or radio-
embolic agents. These minimally invasive image-guided
therapies have revolutionized the management of inoperable
HCC. This review provides a description of all minimally
invasive image-guided therapies currently available, an up-to-
date overview of the scientific evidence for their clinical use,
and thoughts for future directions.
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Introduction
Hepatocellular carcinoma (HCC) is a primary malignant
tumor of the liver that accounts for an important health
problem worldwide. Primary liver cancer is the sixth most
common cancer worldwide with an incidence of 626,000
patients a year, and the third most common cause of cancer-
related death [1]. There is a striking geographic variation in
the incidence of HCC throughout the world [2]. The vast
majority of HCC cases occur in developing countries, but
incidence is on the rise in North America and Europe [3, 4].
HCC is a heterogeneous disease in terms of etiology and
clinical behavior. It usually develops in the setting of chronic
liver disease. Worldwide, the major risk factors for HCC are
infection with the hepatitis B (HBV) and hepatitis C (HCV)
viruses. In developing countries, HCC is mostly related to
chronic HBV carrier state [5, 6]. Preventive vaccination
against HBV infection has proven to effectively reduce the
prevalence of HBV infection [7] and incidence of HCC [8]. In
developed countries, HCC arises in cirrhotic livers related to
hepatitis C virus infection or excessive alcohol intake [9–12].
Accurate staging of the disease helps to determine
prognosis as well as potential therapy with the greatest
survival benefit. Because conventional staging systems, like
the TNM staging system, have shown important limitations
for classifying patients, several new systems have recently
been proposed [13]. Although there is no universally
accepted HCC staging system, many have adopted the
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tion, which links the stage of the disease to a specific
treatment strategy [14] (Fig. 1).
The development of effective therapeutic options for HCC
isamajorchallengeandrequiresamultidisciplinaryapproach.
Only 10–15% of HCC patients are suitable candidates for
hepatic resectionandliver transplantation due tothe advanced
stageofthediseaseattimeofdiagnosisandshortageofdonors
[16]. Surgical resection is restricted to patients with solitary
asymptomatic HCC and preserved liver function who have
no clinically significant portal hypertension or increased
bilirubin [17–19]. Unfortunately, no systemic chemotherapy
has proven to be effective in HCC patients [20], except from
the oral multi-kinase inhibitor Sorafenib in advanced stage
patients with Child-Pugh liver function class A [21]. In order
to provide therapeutic options for patients with inoperable
HCC, several minimally invasive image-guided therapies for
locoregional treatment have been developed. HCC has a
tendency to remain confined to the liver until the disease has
advanced, making these treatments particularly attractive.
Minimally invasive image-guided therapies can be
divided into the group of the tumor ablative techniques or
the group of image-guided catheter-based techniques.
Tumor ablative techniques are either based on thermal
tumor destruction, as in radiofrequency ablation (RFA),
cryoablation, microwave ablation, laser ablation and high-
intensity focused ultrasound (HIFU), or chemical tumor
destruction, as in percutaneous ethanol injection (PEI).
These techniques are mostly used for early stage disease.
Image-guided catheter-based techniques rely on intra-
arterial delivery of embolic, chemoembolic, or radioem-
bolic agents [22]. These techniques enable treatment of
large lesions or whole liver treatment, and are as such used
for intermediate stage HCC (Figure 1).
Minimally invasive image-guided ablation techniques
and intra-arterial interventions may prolong survival, spare
more functioning liver tissue in comparison to surgical
resection (which can be very important in cirrhotic
patients), allow retreatment if necessary, and may be an
effective bridge to transplantation [23–27].
During the last 2 decades, minimally invasive image-
guided therapies have revolutionized the management of
inoperable HCC. This review provides an overview of the
different interventional techniques that are currently avail-
able in clinical practice, the scientific evidence for their
clinical use, and thoughts for future directions.
Fig. 1 Barcelona Clinic Liver Cancer staging and treatment approach.
PS=performance status. N1=lymph node involvement. M1=meta-
static spread. CLT=cadaveric liver transplantation. LDLT=live-donor
liver transplantation. PEI=percutaneous ethanol injection. RF=radio-
frequency. TACE=transarterial chemoembolization. Adapted with
permission from [15]
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Accurate imaging is of great importance during minimally
invasive locoregional therapies to efficiently guide and
monitor the treatment. It enables proper placement of
instruments, like the probe in case of ablation or the
catheter in case of intra-arterial therapy, and accurate
monitoring of the progression of the necrotic zone during
ablation. Fluoroscopy, ultrasound (US), computed tomog-
raphy (CT), and magnetic resonance imaging (MRI) can all
be employed. In current clinical practice, placement of the
catheter in intra-arterial procedures is usually performed
under fluoroscopic guidance, while ablation may be guided
by ultrasound, CT or MRI.
Ultrasound guidance allows probe insertion from every
angle, offers real time visualization and correction for
motion artifacts when targeting the tumor, and is low cost.
However, the gas created during ablation (or ice in the case
of cryoablation) hampers penetration of the ultrasound
beams in tissue, causing acoustic shadowing and obscuring
image details like the delineation between tumor borders
and ablation zone.
CT is also frequently used to guide minimally invasive
ablation therapy, and is a reliable modality to confirm
treatment results. In comparison to US, it provides
increased lesion discrimination, a more reliable depiction
of ablated/non-ablated interfaces, and a better correlation to
pathologic size [28]. However, due to its hypervascularity,
small HCCs can only be clearly visualized in the arterial
phase for a short period of time. Another disadvantage of
CT is the exposure of the patient and physician to ionizing
radiation. Combining US imaging for probe placement and
CT for ablation monitoring reduces this exposure. At the
moment, hybrid systems are being developed, enabling
combination of imaging techniques, like ultrasound and CT
imaging, thereby improving the registration accuracy
during treatment [29].
The interest in MRI-guided ablation is growing, as it
produces a high-quality image allowing high-sensitivity
tumor detectionandaccurateidentificationofthetargetregion
with multiplanar imaging. MRI also enables real-time
monitoring of the temperature evolution during treatment
[30–35]. However, MRI is an expensive technique, and
MRI-guided ablation is still limited in clinical practice.
Tumor ablation techniques
Percutaneous ethanol injection
Prior to the clinical introduction of thermal tumor ablation
techniques, percutaneous ethanol injection (PEI) was
widely used for treatment of HCC. PEI was introduced
into clinical practice in the 1980s, being the first percuta-
neous treatment for HCC [36, 37]. With this technique,
95% ethanol is injected directly into the tumor, using
ultrasound or CT guidance. Ethanol induces local tumor
necrosis as a result of cellular dehydration, protein
denaturation, and chemical occlusion of tumor vessels[38].
Best results are seen with small, uninodular tumors of
3 cm or less, with response rates approaching 100% [39,
40]. Repeated procedures are often needed to obtain
complete tumor ablation, especially for larger lesions.
Three-year survival rates of 79%, 63%, and 12% have
been reported for patients with single HCC of 5 cm or
smaller with Child-Pugh cirrhosis class A, B or C,
respectively [41]. Complications of PEI consist of local
pain, fever, and abscess formation [42].
W h i l eP E Ip r o v e dt ob eav a l u a b l et r e a t m e n tf o r
preferably small HCC lesions, several randomized con-
trolled trials indicate that its effectiveness in small HCCs is
outrun by RFA [39, 43–46]. These studies indicate that
RFA is superior to PEI with respect to overall survival,
cancer-free survival rates, local recurrence, and tumor
response[47]. Nowadays, PEI is used when thermal
ablation such as RFA cannot be performed safely, for
example, in cases in which the tumor is located in close
proximity to bowel loops, bile ducts, or other sites in which
thermal ablative techniques are risky.
Radiofrequency ablation
Currently, the most widely used ablation technique for
percutaneous treatment of focal hepatic malignancies is
radiofrequency ablation (RFA), which has been shown to
be safe and effective for the treatment of early stage HCC
[48–50]. During RFA, a small electrode is placed within the
tumor, and a high-frequency alternating electric current
(approximately 400 MHz) is generated, causing ionic
agitation within the tissue. The movement of ions within
the tissue then creates frictional heat as they try to follow
this alternating current, resulting in high tissue temperatures
inducing coagulative necrosis and cell death. RFA can be
employed via laparotomy (potentially in combination with
surgical resection), laparoscopy or percutaneously. Image
guidance is used for proper electrode placement and to
monitor the progression of the necrotic zone during
ablation. Most frequently ultrasound is used for image
guidance (Figs. 2, 3), but there are reports of groups who
use CT, MRI, or fluoroscopic imaging.
It is difficult to draw definite conclusions about the
efficacy of RFA, as most published data consist of non-
randomized uncontrolled cohort studies. The differences
in outcome measures, techniques, approaches and RFA
electrode designs in these studies add complexity to
interpretation of these data.
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are small size (≤3 cm) tumors and well-differentiated and
non-infiltrative HCCs [51]. Several studies have reported
complete ablation rates of 80–100% in HCCs≤3 cm, 50–
80% in HCCs 3–5 cm, and 25% in HCCs >5 cm[39, 43–45,
51, 52].
Thesurvivalofpatientsaftertreatmentisanotherimportant
indicator of treatment success. Several recent prospective
cohort studies showed long-term survival results similar to
those observed after surgical resection, i.e., 5-year survival
rates 33–63% (Table 1).
RFA is most effective against small tumors; technolog-
ical limitations hinder ablation of tumors with a larger
diameter. Developments in technology, like more powerful
generators or bipolar multiprobe arrays, and technical
maneuvers, like the application of selective vascular
occlusion to reduce the ‘heat sink’ cooling effect of flowing
blood, have allowed treatment of larger tumors [62–67].
Some authors have reported that RFA may be a safe and
effective bridge to liver transplantation over a prolonged
waiting period [23].
Percutaneous image-guided RFA of HCC is associated
with a very low mortality and acceptable morbidity. Three
separate multicenter studies have reported mortality rates
ranging from 0.1% to 0.5%, major complication rates
ranging from 2.2% to 3.1% and minor complication rate
ranging from 5% to 8.9% [68].
One important issue with RFA is the problem of needle-
track seeding, which was reported in one study at a rate of
12.5% [69], although more recent studies show less alarming
rates, ranging from 0.9% to 4% [70–72]. Needle biopsy
before treatment, poor differentiation degree of the tumor,
subcapsular lesions, patients treated in multiple sessions, and
lesions requiring more than one electrode placement were
identified as risk factors. Viable tumor cells adherent to the
needle applicators were found in 12.5% of patients after
ablation without track ablation [73]. To prevent tumor
seeding as well as to create hemostasis, ablation along the
access track is recommended. Despite the risk of needle-
track seeding, RFA is considered a curative treatment for
small HCC lesions, and there is ongoing debate whether
RFA could potentially be considered a first option for
operable patients with very early stage HCC (BCLC stage
0) [74, 75]. In a prospective randomized controlled trial
(RCT) comparing percutaneous RFA to surgical resection in
180 patients with solitary HCCs <5 cm in diameter, no
differences in overall survival rates and cumulative
recurrence-free survival rates were observed [76].
In the BCLC staging classification, patients with early
stage asymptomatic HCC with a single nodule <5 cm or
Fig. 2 Ultrasound guided RFA. a: HCC lesion in a non-surgical patient pre-treatment (pointed out by arrow). b: Just after start treatment,
electrode placed centrally in the tumor. c: Gas formation during ablation causes acoustic shadowing
Fig. 3 Contrast-enhanced CT
pre- and post-RFA. Same
patient as in Fig. 2. a: Hyper-
vascular lesion (biopsy proven
HCC) in right liver lobe
(pointed out by arrow) before
treatment. b: Ablated lesion
directly post ablation, with
reactive hyperemia around the
RFA lesion
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A or B cirrhosis are referred to RFA.
Cryoablation
Cryoablation is a technique in which a liquid nitrogen-
cooled cryoprobe is placed into the tumor and an ice ball is
created in the target tissue. The freezing of tissue with
temperatures between −20°C and −60°C followed by rapid
thawing results in cell membrane disruption and induces
cell death [77]. Cryoablation can be carried out in an open
procedure, by laparoscopy, and percutaneously. Ultrasound
guidance assures proper placement of the cryoprobe and
enables monitoring of the ablation area. An advantage of
this technique is that it can be applied for larger tumors up
to 8 cm, whereas in most tumor ablative techniques only
small tumors can be successfully treated [78]. In most
published studies, cryotherapy was conducted in unresect-
able HCC either alone or in combination with other
treatment modalities, e.g., as a complement to resection to
achieve total tumor eradication in otherwise unresectable
patients, and long-term survival rates of 20–40% have been
described [79, 80]. However, this technique has fallen out
of favor for the treatment of HCC, primarily because of the
complication rate described as high as 40.7% [81] and the
risk of ‘cryoshock,’ a life-threatening condition resulting in
multiorgan failure, severe coagulopathy and disseminated
intravascular coagulation following cryoablation, which has
been described at a rate of 1% [82]. There are currently no
randomized trials that support the use of hepatic cryoa-
blation for HCC treatment.
Microwave ablation
Microwave ablation (MWA) induces thermal tumor destruc-
tion by induction of an alternating electric field emitted by a
bipolar antenna, which is placed centrally in the tumor.
Several groups have successfully proven the safety and
efficacy of MWA treatment, mostly in small HCCs [83, 84].
Dong et al. reported satisfactory long-term results in larger
HCCs. They treated 234 patients with a mean tumor size of
4.1 ± 1.9 cm (range 1.2–8.0 cm) and reported a 5-year
cumulative survival rate of 57%[85]. Liang et al. treated 288
HCC patients with a mean tumor size of 3.75 cm ±1.58
(range 1.2–8.0 cm) and reported a 5-year cumulative survival
rate of 51%. Child-Pugh classification, tumor size, and
Fig. 4 Angiogram during
TACE-DEB procedure. a: Hyper-
vascular HCC caudal right lobe
(segment 6) prior to treatment
(arrow). NB: Patient has multifo-
cal lesions and was previously
treated with Y90 radioemboliza-
tion; workup involved coiling of
the gastroduodenal artery. b:
Precision TACE with DEB
shows embolization of the tumor
microvasculature
Fig. 5 Angiogram during Yttrium-90 radioembolization. a: Replaced
right hepatic artery (normal variant branch from superior mesenteric
artery) vascularizing a large unifocal HCC lesion in the right liver
lobe. b: Selective injection of
90Y microspheres through a micro-
catheter into the right hepatic artery
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prognostic factors. They concluded that there is a signifi-
cantly higher probability of long-term survival after MWA
treatment for patients with a single tumor of 4.0 cm or less
and Child-Pugh class A cirrhosis [86]. Reported complica-
tions of MWA are similar to those reported for RFA and are
typically mild, including pain, fever, liver enzyme elevation,
ascites, pleural effusion, and diaphragm injury.
MWA has been compared to other ablative techniques in
several studies. Seki et al. retrospectively compared MWA
to PEI for small HCCs (≤2 cm). They concluded that MWA
may be superior to PEI for the local control of moderately
or poorly differentiated small HCCs [87]. Ohmoto et al.
compared MWA to RFA for small HCCs. They suggested
that RFA is more useful for the treatment of small HCCs
(≤2 cm) compared to MWA, since RFA resulted in a larger
area of necrosis, needed fewer treatment sessions, and
showed a lower recurrence rate and higher survival rate
(4-year survival 70% versus 39%) [88–90]. However, Lu et
al. performed a retrospective comparative study and
concluded that MWA and RFAwere both effective methods
in treating HCC [mean tumor diameter respectively 2.5 cm
±1.2 (range 0.9–7.2 cm) and 2.6 cm ±1.2 (range 1.0–
6.1 cm)]. Local tumor control, complications related to
treatment, and long-term survival (4-year survival 37% for
MWA versus 24% for RFA, P=0.12) were equivalent for
the two modalities [91]. It needs to be noted that the level
of evidence of these studies is limited since they describe
only a retrospective comparison of the two procedures. The
only randomized study comparing MWA and RFA showed
that both techniques had equivalent therapeutic effects,
complication rates, and rates of residual foci of untreated
disease. However,RFAofferstheadvantageoftumorablation
being achieved in fewer sessions (2.4 versus 1.1) [92].
In conclusion, experience with MWA of HCC is limited
and still in its early stage. Preliminary work has shown that
microwave ablation might be a viable alternative to other
ablation techniques. Further prospective randomized studies
evaluating local control, symptom palliation, and survival
in a larger number of patients are necessary.
Fig. 6 Pre- and post-Yttrium-90
radioembolization. a: Fusion
image of liver MRI and 99mTc-
MAA scintigram showing large
HCC lesion in right liver lobe.
b: Contrast-enhanced MRI
3 months post-treatment shows
necrotic zone centrally in HCC
Study Patients (n) Type of
RFA
Tumor size
(cm)
5-year overall
survival (%)
Buscarini et al. (2001)[53] 88 perc ≤3.5 33
Lencioni et al. (2005)[54] 187 perc Mean, 2.8 48
Tateishi et al. (2005)[55] 319 (naive) perc Mean, 2.6 54 (naive)
345 (pretreated) 38 (pretreated)
Raut et al. (2005)[56] 194 140 perc Median 55
54 open Total 3.3
Perc 3.0
Open 4.0
Machi et al. (2005)[57] 84 49 perc Mean 40
20 lap Total 3.2
15 open Perc 3.2
Lap 3.0
Open 3.1
Cabassa et al. (2006)[58] 59 perc Mean, 3.1 43
Choi et al. (2006)[59] 570 perc Mean, 2.59 58
Yan et al. (2007)[60] 266 perc Mean, 3.9 43
Ueno et al. (2009)[61] 155 110 perc, 45 Mean, 2.0 63
lap/open
Table 1 Long-term survival
data from follow-up studies of
HCC patients treated with RFA
Data of studies with≥50 patients
included
RFA=radiofrequency ablation,
perc=percutaneous, lap=laparo-
scopic, open=open procedure
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In laser ablation, also frequently called laser-induced
thermotherapy (LITT), a percutaneously placed optical
fiber delivers laser beams into the target tumor [93]. The
energy from the photons absorbed in the tissue converts
into heat, inducing coagulative necrosis. The most com-
monly used device for laser ablation is the Nd-YAG laser
(neodymium-yttrium-aluminum-garnet laser). Most fre-
quently, near-infrared wavelength optical radiation is used,
since this accomplishes the best tissue penetration [94]. The
positioning of the fibers is guided by ultrasound, CT, or
MRI. A single-probe insertion can only create a small
volume of ablation, so often multiple optical fibers have to
be placed for treatment of larger lesions (>5 cm), which
may be technically cumbersome and result in long
treatment times. Selection criteria for LITT are broadly
similar to those of other ablative techniques. Ideal lesions
are less than 3 cm in diameter and located deep within the
liver parenchyma [95].
LITT has been proven safe and feasible for the treatment
of HCCs in multiple cohort studies[96–102]. Pacella et al.
performed three studies in which they reported 3- and
5-year survival rates ranging from 52% to 68% and 15% to
34%, respectively [96, 98, 99]. They included patients with
a single nodule≤4 cm or three nodules≤3 cm each. Tumor
size, tumor location, and the achievement of complete
response were important factors that affected survival after
treatment. They stated that the ideal candidates for LITT are
those with normal bilirubin levels and a small tumor size
(≤2c m )[ 97–99]. According to Arienti et al., who
performed a multicenter study with 353 patients to
investigate complications, LITT is a safe treatment with a
major complication rate of 1.5% (0.8% deaths) and a minor
complication rate of 6.2%. They also stated that complete
response was achieved in 60%, regardless of tumor size,
and in 81% in lesions≤3 cm HCCs [102]. Tumor seeding
after treatment has not been reported. LITT has also been
proven safe and effective for the treatment of cirrhotic
patients awaiting liver transplantation[103]. There is one
randomized trial in which LITT is compared to RFA for
treatment of early stage HCC (nodule≤4 cm or three
nodules≤3 cm each). They found LITT and RFA to be
equally effective; however, in the case of RFA fewer
treatment sessions were needed to achieve complete
response [104]. More randomized controlled trials should
be carried out to compare LITT to other ablative techniques
and to investigate the role of LITT in combination therapy.
High-intensity focused ultrasound
In high-intensity focused ultrasound (HIFU), an extracor-
poreal transducer produces high-energy ultrasound (US)
beams that propagate harmlessly through the intact skin and
are brought into a tight focus (1–3 mm) within the tumor.
The rapid deposition of acoustic energy leads to an
instantaneous temperature increase of >55°C within the
tissue, inducing coagulation necrosis [105]. HIFU offers the
first completely non-invasive approach to HCC and is
therefore a promising technology. In current practice, both
conventional ultrasound and MRI are used to guide and
monitor HIFU treatment. MRI offers one important advan-
tage over US guidance, as it enables accurate monitoring of
the temperature during treatment [30].
There are only a few clinical reports on the applica-
tion of HIFU for HCC treatment. The majority of work
is published by two groups [106, 107] ,w h ob o t hu s er e a l -
time US-guidance during treatment. Wu et al. report that
HIFU treatment is effective, safe, and feasible in patients
with large HCCs [106]. They treated 55 patients with a
m e a nt u m o rd i a m e t e ro f8 . 1 4c m±3 . 3 7( r a n g e4 - 1 4c m ).
Overall survival rates at 6, 12, and 18 months were
respectively 86.1%, 61.5%, and 35.3%. The survival rates
were higher in patients with less advanced disease
according to the TNM classification. It has to be noted
however that pre-procedural TACE was carried out in half
of the patients and that rib resection was performed in 14
patients, taking away the non-invasive character of the
procedure. In another study by Zhu et al., ribs were
removed in all patients to create a better acoustic pathway.
Sixteen HCC patients were treated with US-guided HIFU
with a mean tumor diameter of 7.0 cm ± 2.1 (range 5–
10 cm). The 3- and 5-year survival rates were 69.3% and
55.6%, respectively [107]. As the results of these studies
indicate, there are some difficulties that need to be
overcome before HIFU can be used in everyday clinical
practice for non-invasive treatment of HCC. The presence
of the rib cage presents a problem, since the high
attenuation of the ribs results in a loss of power at the
focus, and reflection of the beams may induce injury to the
overlying soft tissues and the skin, which may also happen
when US encounters an air-filled bowel loop. However,
technical solutions are underway. Civale et al. reported
that this problem can be avoided by the use of a
segmented transducer [108]. Liu et al. proposed to reduce
the rib-overheating problem by using an independent
array-element activation scheme, which switches off the
transducer elements obstructed by the ribs based on
feedback anatomical medical imaging [109]. Another
challenge in HIFU for HCC treatment is the difficulty in
targeting and monitoring since the liver is subject to
respiratory movements. The main limitation to clinical use
of HIFU is the fact that ablation of large volumes of the
liver is still very time consuming. Next-generation phased-
array transducers and advanced MRI methods are being
developed to overcome these difficulties.
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Transcatheter arterial chemoembolization
Transcatheter arterial chemoembolization (TACE) is a
technique that exploits the dual blood supply to the liver.
HCC derives its blood supply almost entirely from the
hepatic artery, while normal liver parenchyma derives
>75% of its blood supply from the portal vein [110]. This
anatomical fact provides the basis for the development of
arterial therapies for the treatment of HCC, with the
potential to selectively induce tumor necrosis while
surrounding liver parenchyma is spared.
In TACE, a catheter is advanced into the branches of the
hepatic artery directly supplying the tumor, and a highly
concentrated dose of chemotherapy is delivered intra-
arterially in close proximity to the tumor so that systemic
toxicity is minimized. The most commonly used single
chemotherapeutic agent is doxorubicin. The combination of
cisplatin, doxorubicin, and mitomycin C is the most common
combination drug regimen. However, to date there is no
evidence of the superiority of any chemotherapeutic agent
aloneorofmonotherapyversuscombinationtherapyinTACE
[111, 112]. The chemotherapeutic agent is usually mixed
with an embolic agent such as lipiodol, an oily contrast
medium used as a carrier for the chemotherapeutic agent and
known to be selectively retained inside the tumor, thereby
prolonging contact time between the drugs and the tumor
cells [113, 114]. The administration of the lipiodolized
chemotherapeutic agent is followed by injection of an
occluding agent. The purpose of the embolization is to
reduce arterial inflow, resulting in ischemic tumor necrosis,
and to diminish washout of the chemotherapeutic agent
thereby prolonging contact time between cancer cells and the
chemotherapeutic agent [115]. Multiple TACE protocols are
used throughout the world, and the optimal method is yet to
be established.
Assessing the efficacy of TACE is difficult due to its lack of
standardization,andoutcomesofdifferentcentersarenot easily
compared. As in other ablative techniques, the best measure of
success is patient survival. Two RCTs [116, 117]a n da
systematic review [118] showed that TACE improves survival
when compared to conservative treatment, provided there is a
restrictive selection of candidates (Table 2). Ideal candidates
for TACE are patients with multinodular asymptomatic
tumors without vascular invasion or extrahepatic spread and
well-preserved liver function (Child-Pugh class A).
TACE is typically well tolerated. The major side effect of
TACE is the so-called postembolization syndrome, consisting
of transient abdominal pain, ileus, and fever, probably due to
damage of hepatocytes. It effects 40%–85% of patients and is
usuallyself-limitedwithin48h[123]. A serious complication
of TACE is acute liver failure. The potential risk for this
condition, which increases with larger tumors, underlying
liver dysfunction and presence of portal vein thrombosis,
limits the use of TACE. Other more serious treatment-related
complications (hepatic abcess, ischemic cholecystitis, biliary
strictures) appear in less than 10% of treatment sessions
[124]. The side effects of the chemotherapeutic agents in
TACE are mild and have a low rate, compared with those
caused by systemic chemotherapy, and can be managed
conservatively. They include nausea, vomiting, bone marrow
depression, alopecia, and renal dysfunction [125, 126].
To conclude, TACE is currently the treatment of choice
for multinodular, intermediate stage HCC (Fig. 1, BCLC
stage B) and to be preferred over best supportive care.
Transcatheter arterial (bland) embolization
Transcatheter arterial embolization (TAE or bland emboliza-
tion) consists of embolizing the artery feeding the tumor,
withouttheuseofachemotherapeuticagent.Theexactbenefit
of administering chemotherapy during the embolization
procedure is uncertain, since HCC is known to be chemo-
resistant.However,hypoxiaisknowntobeapotentstimulator
of angiogenesis, and since angiogenesis is vital for tumor
growth,hypoxia inducedbyembolizationmight inadvertently
promote tumor growth [127]. Adding a chemotherapeutic
agent may counteract this effect. No comparative clinical
study to date has proven evidence of survival favoring TACE
over TAE [112]. However, in recent years, TACE has
replaced TAE as the most widely used and studied treatment
modality for intermediate stage HCC [128].
TACE-DEB
Although conventional TACE has been shown to improve
survival, the magnitude of this benefit is relatively small, so
the search for more effective drug delivery systems
continues. A novel development in the treatment for HCC
is the drug-eluting bead (DEB), a polyvinyl alcohol-based
microsphere loaded with a chemotherapeutic agent, usually
doxorubicin. These microspheres are available in diameters
ranging from 40 to 1,200 µm. The DEB is delivered intra-
arterially in a manner similar to that of conventional TACE
and acts as both an occluding agent as well as a drug-loaded
carrier (Fig. 4). Local ischemia and toxic death of the tumor
are achieved with one device, enabling standardization.
DEBs have favorable kinetics achieving higher tumor
concentrations with lower plasma levels of the chemo-
therapic agent compared to conventional TACE [129, 130].
In DEBs, drug elution is dependent on ion exchange with
the surrounding environment. This results in a controlled
and sustained gradual release of the drug—unlike the more
rapid separation of the drug from lipiodol—prolonging the
exposure of tumor cells [131].
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DEBs in the treatment of intermediate stage HCC [130,
132–135], with good objective response (complete plus
partial response) rates ranging 60%–85.5% (according to
the EASL response criteria). The complication rates in
these clinical trials ranged between 3 and 11.4%, and post-
embolisation syndrome was observed in various severities
in 18% [135], 37% [130] and 100% [133, 134]. Most
important, there are no reports of systemic toxicity, despite
the high doses of doxorubicin loaded on the DEBs.
Information on survival rates is still limited up to today,
but midterm survival rates seem promising with 2-year
survival up to 91% [134]. RCTs comparing conventional
TACE to TACE-DEB are currently underway.
Yttrium-90 radioembolization
Theuseoftraditionalexternalbeamradiationforthetreatment
of HCC has been limited because of the inability to deliver an
effective dose without damaging the adjacent hepatic paren-
Study Patients
(n)
Therapy 1-year
overall
survival (%)
2-year
overall
survival (%)
3-year
overall
survival (%)
Lin et al. (1988)[119] 63 21 TAE 42 25 NR
21 TAE+5-FU iv 20 20 NR
21 5-FU iv 13 13 NR
Pelletier et al. (1990)[120] 42 21 TACE 24 NR NR
21 Conservative 31 NR NR
Groupe d’Etude (1995)[121] 96 50 TACE 62 38 NR
46 Conservative 43 26 NR
Pelletier et al. (1998)[122] 73 37 TACE 51 24 NR
36 Tamoxifen 55 26 NR
Lo et al. (2002)[117] 79 40 TACE 57 31 26
39 Conservative 32 11 3
Llovet et al. (2002)[116] 112 40 TACE 82 63 29
3 7 T A E 7 55 02 9
35 Conservative 63 27 17
Table 2 Survival data from
randomized controlled trials
investigating TACE in HCC
patients
TACE=transcatheter arterial
chemoembolization, TAE=
transcatheter arterial (bland)
embolization, NR=not reported
Table 3 Tumor response and median survival after
90Y-RE in HCC patients
Study Patients (n) Tumor response on CT
a Median survival (months) Microspheres
CR (%) PR (%) SD (%) PD (%)
Lau et al. (1998)[142] 71 0 27 65 8 9.4 Resin
Dancey et al. (2000) [143] 20 (19 evaluated for
response)
5 16 58 21 12.5 Glass
Carr et al. (2004)[144] 65 NR 38 NR NR Okuda I: 21.3, Okuda II: 9.9 Glass
Geschwind et al. (2004)[145] 80 NR NR NR NR Okuda I: 20.6, Okuda II: 12.6 Glass
Goin (2005)[146] 121 NR NR NR NR Low risk: 15.3, high risk: 3.5 Glass
Salem (2005)[147] 43 NR 47 (79
b) NR NR Okuda I: 24.4, Okuda II: 12.5 Glass
Sangro (2006)[148] 24 (21 evaluated for
response)
NR 88
c (PR+SD) NR 7 Resin
Young (2007)[149] 41 NR NR NR NR Okuda I: 21.7, Okuda II: 14.2 Glass
Kulik (2008)[150] 108 NR 42.2 (70
b) 34.7 23.1 No PVT: 15.4, branch PVT: 10.0,
main PVT: 4.4
Glass
Data of studies including ≥20 patients
CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease
PVT=portal vein thrombosis, NR=not reported
aWHO criteria unless otherwise explained
bEASL modified WHO criteria[151]
cRECIST criteria[152]
Insights Imaging (2010) 1:167–181 175chyma, resulting in radiation-induced liver disease (RILD),
previously called radiation-induced hepatitis [136–138].
Radioembolization (RE) implements intra-arterial adminis-
tration of microspheres coated with yttrium-90 (
90Y), a ß-
emitting isotope, delivering selective internal radiation to the
tumor. Exposure to surrounding healthy tissue is limited,
avoiding injury to the normal liver parenchyma [139]. This
technique was first described in 1965[140], and in recent
years clinical investigation has intensified. The procedure is
compromised by two components: embolization, with a
micro-or macro-embolic effect, depending on the size of the
microsphere, and brachytherapy [139, 141]( F i g s .5, 6). Two
types of Y90 microspheres are in clinical use at present:
glass microspheres (TheraSphere
®, MDS Nordion Inc.,
Kanata, Canada) and resin-based microspheres (SIR-
Spheres
®, SIRTeX Medical Ltd., Sydney, Australia).
The safety and efficacy of
90Y-RE treatment for
unresectable HCC has been documented, although there
are no long-term survival data from randomized controlled
trials to date. Table 3 summarizes the experience published
on HCC treatment with
90Y-RE.
90Y-RE has a low toxicity profile and can be performed
on an outpatient basis, with low incidence of a mild post-
embolization syndrome [147, 153]. Due to the minimally
embolic effect of
90Y-RE glass microspheres, this offers a
safe treatment with favorable tumor response rates for
patients with portal vein thrombosis [150].
Absolute contraindications for
90Y-RE treatment are
significant hepatopulmonary shunting or flow to the
gastrointestinal tract that cannot be corrected by catheter
manipulation, demonstrated by a pre-treatment
99mTc
macro-aggregated albumin (MAA) examination [154].
Inadvertent deposition of
90Y microspheres to the lungs or
gastrointestinal tract can result in serious complications like
radiation pneumonitis, cholecystitis, gastric ulceration, or
pancreatitis pneumonitis[154–157]. The antitumor effect of
90Y-RE allows for the downstaging of unresectable HCC to
potentially curative treatments, like surgical resection,
percutaneous ablation, and bridging to liver transplanta-
tion[158–160]. Although several studies have provided
useful data, there is a need for further investigation of this
therapy and randomized trials comparing the efficacy of
90Y-RE to other minimally invasive locoregional therapies.
Conclusion
HCC is a heterogeneous cancer with an increasing
incidence and poor prognosis. Curative therapy is only
applicable to patients diagnosed at early stages of disease,
emphasizing the importance of screening programs for
at-risk patients. Minimally invasive image-guided ablation
techniques and intra-arterial interventions offer promising
potential for patients with HCC not suitable for surgical
resection or transplantation.
According to the BCLC criteria, RFA is currently
considered the treatment of choice for patients with
unresectable small HCCs (early stage, stage A). TACE is
the treatment of choice for the management of multinodular
HCC (intermediate stage, stage B), preferably in asymp-
tomatic patients with well-preserved liver function (Child-
Pugh class A). Sorafenib, an oral multitargeted tyrosine
kinase inhibitor, has become the standard of care in
advanced stage patients (stage C) with vascular involve-
ment, extrahepatic spread or physical impairment (Child-
Pugh A, ECOG performance status test score 1–2).
Targeted molecular therapies like Sorafenib represent the
beginning of a new era in the treatment of HCC. Finally,
patients at a terminal stage (stage D) who have very impaired
physical status (performance status test score >2) or tumor
burden (stage D) should receive symptomatic treatment.
For most tumor ablative techniques, increasing tumor
diameter decreases the likelihood of complete ablation. The
combination of local ablation and intra-arterial therapies
may help overcome shortcomings of monotherapy treat-
ment for larger tumors, and diverse studies have shown
promising potential.
A randomized controlled study showed that concomitant
RFA-PEI facilitated better local tumor control and long-
term survival compared to RFA alone, with 5-year overall
survival rates of 49.3% versus 35.9% [161]. A meta-
analysis of four randomized controlled trials [162–165] that
investigated the combination of TACE or TAE plus
percutaneous ablation (PEI or RFA) for the treatment of
HCC showed a significant decrease in mortality favoring
combination treatment compared to monotherapy (TAE,
TACE, or percutaneous ablation only)[166]. In addition,
there is high interest in combining local therapies with
targeted molecular therapies like Sorafenib.
With ongoing research, existing image-guided local
therapies will be further optimized, and promising new
therapies will emerge. Combination of treatments, new
technologies in imaging, and targeted drug delivery will
ultimately improve the quality of life and survival of
patients with HCC.
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